Share Price and Basic Stock Data
Last Updated: November 14, 2025, 10:08 pm
| PEG Ratio | -249.41 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Sakar Healthcare Ltd operates within the Hospitals & Medical Services sector and has reported a market capitalization of ₹789 Cr. The company’s stock price stood at ₹354, reflecting a P/E ratio of 39.8, which suggests a premium valuation compared to many peers in the sector. Over the last fiscal year, Sakar recorded revenues of ₹133 Cr, with a trailing twelve-month (TTM) revenue of ₹189 Cr, indicating a steady upward trajectory in sales. The quarterly sales figures demonstrate this growth, with revenues rising from ₹28.53 Cr in June 2022 to ₹40.65 Cr in March 2023, before reaching ₹43.06 Cr in March 2024. The company’s ability to increase sales, even amidst fluctuations, highlights its resilience and market positioning. The operating profit margin (OPM) stood at 24.10%, underscoring a solid operational efficiency and profitability level that is competitive compared to industry standards.
Profitability and Efficiency Metrics
Sakar Healthcare’s profitability metrics reflect a mixed performance. The return on equity (ROE) was recorded at 6.48%, while the return on capital employed (ROCE) stood at 8.54%. These figures indicate that while the company is generating returns on its equity and capital, they are relatively low compared to higher-performing peers in the healthcare sector. The net profit for the last fiscal year was ₹20 Cr, with a net profit margin of 9.85% in the latest reporting period, which is slightly below the typical industry margin range. The company’s interest coverage ratio (ICR) was reported at 5.98x, suggesting a strong capacity to meet interest obligations. However, the cash conversion cycle (CCC) stood at 163 days, indicating potential inefficiencies in managing working capital. The combination of these metrics suggests that while Sakar Healthcare is profitable, there are areas for improvement in operational efficiency and profitability margins.
Balance Sheet Strength and Financial Ratios
Sakar Healthcare’s balance sheet reveals a reasonable financial structure, with total borrowings at ₹86 Cr against reserves of ₹264 Cr, indicating a conservative leverage position. The debt-to-equity ratio was reported at 0.26, suggesting that the company is utilizing a modest amount of debt to finance its operations. The current ratio was recorded at 1.40, reflecting a healthy liquidity position, while the quick ratio stood at 0.71, indicating potential liquidity challenges if immediate liabilities were to come due. The book value per share increased to ₹130.06, showcasing solid capital retention and growth. The enterprise value (EV) at ₹539.37 Cr highlights the company’s market valuation relative to its operational performance. However, the increase in inventory days to 193 indicates a slowdown in inventory turnover, which could pose risks to liquidity and operational efficiency if not addressed promptly.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Sakar Healthcare demonstrates a diverse ownership structure, with promoters holding 52.86% of the equity, down from 62.10% in September 2022. This decline in promoter stake may raise concerns regarding long-term commitment. Foreign Institutional Investors (FIIs) accounted for 13.41% of the shareholding, while Domestic Institutional Investors (DIIs) held 11.25%. The public shareholding constituted 22.48%, reflecting a healthy distribution among retail investors. The number of shareholders increased to 8,115, indicating growing interest in the company. However, the gradual reduction in promoter shareholding could signal a lack of confidence or a strategic repositioning, which may affect investor sentiment. The overall ownership structure suggests a balanced approach to governance but highlights the need for continuous engagement with shareholders to maintain confidence.
Outlook, Risks, and Final Insight
Sakar Healthcare’s outlook appears cautiously optimistic, driven by its solid revenue growth and operational profitability. However, challenges such as the high cash conversion cycle and relatively low ROE and ROCE could hinder its performance in a competitive healthcare market. Risks include potential liquidity issues stemming from increased inventory days and reliance on external debt, which could impact financial stability. Additionally, fluctuations in the shareholding pattern, particularly the decline in promoter holdings, may lead to investor uncertainty. To capitalize on growth opportunities, Sakar may need to enhance operational efficiencies and improve working capital management. If these issues are addressed, the company could strengthen its market position and drive higher shareholder returns in the long term.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Sakar Healthcare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 43.8 Cr. | 131 | 195/125 | 8.94 | 117 | 2.68 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 25.6 Cr. | 24.4 | 35.5/0.00 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 13.4 Cr. | 13.0 | 21.4/11.6 | 149 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 123 Cr. | 65.5 | 98.7/52.0 | 27.1 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 21.1 Cr. | 3.90 | 7.60/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 27,688.79 Cr | 847.22 | 103.06 | 99.08 | 0.31% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28.53 | 30.71 | 33.47 | 40.65 | 38.99 | 34.08 | 37.23 | 43.06 | 41.15 | 42.78 | 43.42 | 50.24 | 52.74 |
| Expenses | 20.57 | 22.12 | 24.67 | 32.87 | 29.96 | 24.72 | 28.22 | 32.09 | 30.45 | 31.28 | 31.66 | 34.52 | 40.03 |
| Operating Profit | 7.96 | 8.59 | 8.80 | 7.78 | 9.03 | 9.36 | 9.01 | 10.97 | 10.70 | 11.50 | 11.76 | 15.72 | 12.71 |
| OPM % | 27.90% | 27.97% | 26.29% | 19.14% | 23.16% | 27.46% | 24.20% | 25.48% | 26.00% | 26.88% | 27.08% | 31.29% | 24.10% |
| Other Income | 0.41 | 0.60 | 1.85 | 1.81 | 1.52 | 0.66 | 0.23 | 0.77 | 0.46 | 0.37 | 0.25 | 0.18 | 0.39 |
| Interest | 0.86 | 0.99 | 1.94 | 2.15 | 2.08 | 1.65 | 1.79 | 2.08 | 1.40 | 1.64 | 1.30 | 4.19 | 2.14 |
| Depreciation | 3.57 | 3.77 | 4.10 | 3.55 | 4.52 | 4.22 | 4.44 | 4.87 | 5.06 | 5.12 | 5.23 | 5.48 | 5.57 |
| Profit before tax | 3.94 | 4.43 | 4.61 | 3.89 | 3.95 | 4.15 | 3.01 | 4.79 | 4.70 | 5.11 | 5.48 | 6.23 | 5.39 |
| Tax % | 26.90% | 56.21% | 13.02% | -0.77% | 28.10% | 12.53% | 30.90% | 34.86% | 48.72% | 6.07% | 17.15% | 7.70% | 13.17% |
| Net Profit | 2.88 | 1.94 | 4.01 | 3.92 | 2.84 | 3.64 | 2.07 | 3.12 | 2.41 | 4.80 | 4.53 | 5.76 | 4.67 |
| EPS in Rs | 1.68 | 1.04 | 2.15 | 2.06 | 1.49 | 1.70 | 0.95 | 1.43 | 1.11 | 2.21 | 2.06 | 2.62 | 2.13 |
Last Updated: August 1, 2025, 12:55 pm
Below is a detailed analysis of the quarterly data for Sakar Healthcare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 52.74 Cr.. The value appears strong and on an upward trend. It has increased from 50.24 Cr. (Mar 2025) to 52.74 Cr., marking an increase of 2.50 Cr..
- For Expenses, as of Jun 2025, the value is 40.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 34.52 Cr. (Mar 2025) to 40.03 Cr., marking an increase of 5.51 Cr..
- For Operating Profit, as of Jun 2025, the value is 12.71 Cr.. The value appears to be declining and may need further review. It has decreased from 15.72 Cr. (Mar 2025) to 12.71 Cr., marking a decrease of 3.01 Cr..
- For OPM %, as of Jun 2025, the value is 24.10%. The value appears to be declining and may need further review. It has decreased from 31.29% (Mar 2025) to 24.10%, marking a decrease of 7.19%.
- For Other Income, as of Jun 2025, the value is 0.39 Cr.. The value appears strong and on an upward trend. It has increased from 0.18 Cr. (Mar 2025) to 0.39 Cr., marking an increase of 0.21 Cr..
- For Interest, as of Jun 2025, the value is 2.14 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.19 Cr. (Mar 2025) to 2.14 Cr., marking a decrease of 2.05 Cr..
- For Depreciation, as of Jun 2025, the value is 5.57 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.48 Cr. (Mar 2025) to 5.57 Cr., marking an increase of 0.09 Cr..
- For Profit before tax, as of Jun 2025, the value is 5.39 Cr.. The value appears to be declining and may need further review. It has decreased from 6.23 Cr. (Mar 2025) to 5.39 Cr., marking a decrease of 0.84 Cr..
- For Tax %, as of Jun 2025, the value is 13.17%. The value appears to be increasing, which may not be favorable. It has increased from 7.70% (Mar 2025) to 13.17%, marking an increase of 5.47%.
- For Net Profit, as of Jun 2025, the value is 4.67 Cr.. The value appears to be declining and may need further review. It has decreased from 5.76 Cr. (Mar 2025) to 4.67 Cr., marking a decrease of 1.09 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.13. The value appears to be declining and may need further review. It has decreased from 2.62 (Mar 2025) to 2.13, marking a decrease of 0.49.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:32 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30 | 35 | 41 | 44 | 53 | 68 | 83 | 95 | 128 | 133 | 153 | 178 | 204 |
| Expenses | 22 | 27 | 33 | 34 | 40 | 51 | 63 | 72 | 99 | 100 | 115 | 128 | 152 |
| Operating Profit | 8 | 8 | 8 | 10 | 13 | 17 | 20 | 23 | 29 | 33 | 38 | 50 | 52 |
| OPM % | 26% | 22% | 20% | 23% | 24% | 25% | 24% | 24% | 23% | 25% | 25% | 28% | 25% |
| Other Income | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 2 | 5 | 3 | 1 | 2 |
| Interest | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 6 | 8 | 9 | 9 |
| Depreciation | 2 | 2 | 3 | 3 | 4 | 6 | 7 | 8 | 10 | 15 | 18 | 21 | 22 |
| Profit before tax | 2 | 2 | 3 | 5 | 6 | 9 | 12 | 13 | 19 | 17 | 16 | 22 | 22 |
| Tax % | 13% | 24% | 22% | 30% | 38% | 28% | 21% | 19% | 20% | 24% | 27% | 19% | |
| Net Profit | 2 | 2 | 2 | 3 | 4 | 7 | 10 | 11 | 15 | 13 | 12 | 18 | 20 |
| EPS in Rs | 2.19 | 2.30 | 2.78 | 3.08 | 3.12 | 4.47 | 6.43 | 6.84 | 8.90 | 6.70 | 5.37 | 7.97 | 8.82 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 50.00% | 33.33% | 75.00% | 42.86% | 10.00% | 36.36% | -13.33% | -7.69% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 50.00% | -16.67% | 41.67% | -32.14% | -32.86% | 26.36% | -49.70% | 5.64% | 57.69% |
Sakar Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 16% |
| 3 Years: | 11% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 13% |
| 3 Years: | 5% |
| TTM: | 76% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 36% |
| 3 Years: | 13% |
| 1 Year: | 6% |
| Return on Equity | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 1:15 pm
Balance Sheet
Last Updated: November 9, 2025, 2:51 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 11 | 12 | 15 | 15 | 16 | 17 | 19 | 22 | 22 | 22 |
| Reserves | 6 | 7 | 11 | 25 | 39 | 57 | 66 | 83 | 110 | 154 | 241 | 264 | 281 |
| Borrowings | 24 | 25 | 22 | 24 | 11 | 11 | 17 | 43 | 93 | 119 | 79 | 86 | 72 |
| Other Liabilities | 14 | 11 | 10 | 11 | 18 | 15 | 17 | 37 | 47 | 44 | 47 | 43 | 73 |
| Total Liabilities | 52 | 50 | 51 | 71 | 81 | 97 | 115 | 178 | 268 | 336 | 389 | 415 | 449 |
| Fixed Assets | 38 | 36 | 37 | 49 | 53 | 64 | 66 | 69 | 205 | 267 | 314 | 309 | 325 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 9 | 13 | 49 | 1 | 6 | 0 | 17 | 17 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 3 | 0 | 0 | 0 |
| Other Assets | 14 | 14 | 14 | 22 | 28 | 25 | 36 | 60 | 55 | 60 | 74 | 90 | 107 |
| Total Assets | 52 | 50 | 51 | 71 | 81 | 97 | 115 | 178 | 268 | 336 | 389 | 415 | 449 |
Below is a detailed analysis of the balance sheet data for Sakar Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00 Cr..
- For Reserves, as of Sep 2025, the value is 281.00 Cr.. The value appears strong and on an upward trend. It has increased from 264.00 Cr. (Mar 2025) to 281.00 Cr., marking an increase of 17.00 Cr..
- For Borrowings, as of Sep 2025, the value is 72.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 86.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 14.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 73.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 43.00 Cr. (Mar 2025) to 73.00 Cr., marking an increase of 30.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 449.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 415.00 Cr. (Mar 2025) to 449.00 Cr., marking an increase of 34.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 325.00 Cr.. The value appears strong and on an upward trend. It has increased from 309.00 Cr. (Mar 2025) to 325.00 Cr., marking an increase of 16.00 Cr..
- For CWIP, as of Sep 2025, the value is 17.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 17.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 107.00 Cr.. The value appears strong and on an upward trend. It has increased from 90.00 Cr. (Mar 2025) to 107.00 Cr., marking an increase of 17.00 Cr..
- For Total Assets, as of Sep 2025, the value is 449.00 Cr.. The value appears strong and on an upward trend. It has increased from 415.00 Cr. (Mar 2025) to 449.00 Cr., marking an increase of 34.00 Cr..
Notably, the Reserves (281.00 Cr.) exceed the Borrowings (72.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -16.00 | -17.00 | -14.00 | -14.00 | 2.00 | 6.00 | 3.00 | -20.00 | -64.00 | -86.00 | -41.00 | -36.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28 | 21 | 26 | 44 | 74 | 51 | 36 | 48 | 40 | 60 | 50 | 63 |
| Inventory Days | 190 | 142 | 107 | 114 | 51 | 70 | 92 | 112 | 69 | 76 | 121 | 193 |
| Days Payable | 97 | 20 | 66 | 51 | 57 | 41 | 46 | 141 | 149 | 129 | 120 | 93 |
| Cash Conversion Cycle | 120 | 143 | 67 | 107 | 68 | 80 | 83 | 19 | -39 | 7 | 51 | 163 |
| Working Capital Days | -8 | 27 | 10 | 67 | 98 | 31 | 31 | 2 | -11 | -6 | 29 | 52 |
| ROCE % | 15% | 14% | 14% | 15% | 14% | 16% | 16% | 13% | 12% | 9% | 7% | 9% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 7.97 | 5.63 | 6.75 | 8.73 | 6.84 |
| Diluted EPS (Rs.) | 7.95 | 5.63 | 6.75 | 8.73 | 6.84 |
| Cash EPS (Rs.) | 17.49 | 13.66 | 14.57 | 14.52 | 12.00 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 130.06 | 120.61 | 91.04 | 74.46 | 63.04 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 130.06 | 120.61 | 91.04 | 74.46 | 63.04 |
| Revenue From Operations / Share (Rs.) | 80.90 | 70.51 | 70.04 | 74.91 | 60.66 |
| PBDIT / Share (Rs.) | 23.23 | 19.10 | 19.86 | 18.40 | 15.22 |
| PBIT / Share (Rs.) | 13.72 | 10.80 | 11.99 | 12.75 | 10.06 |
| PBT / Share (Rs.) | 9.81 | 7.31 | 8.87 | 11.06 | 8.47 |
| Net Profit / Share (Rs.) | 7.97 | 5.37 | 6.70 | 8.87 | 6.84 |
| NP After MI And SOA / Share (Rs.) | 7.97 | 5.37 | 6.70 | 8.87 | 6.84 |
| PBDIT Margin (%) | 28.71 | 27.08 | 28.35 | 24.56 | 25.09 |
| PBIT Margin (%) | 16.95 | 15.31 | 17.11 | 17.02 | 16.58 |
| PBT Margin (%) | 12.12 | 10.36 | 12.65 | 14.76 | 13.96 |
| Net Profit Margin (%) | 9.85 | 7.61 | 9.56 | 11.83 | 11.27 |
| NP After MI And SOA Margin (%) | 9.85 | 7.61 | 9.56 | 11.83 | 11.27 |
| Return on Networth / Equity (%) | 6.13 | 4.44 | 7.36 | 11.90 | 10.85 |
| Return on Capital Employeed (%) | 8.55 | 7.12 | 8.10 | 9.87 | 10.87 |
| Return On Assets (%) | 4.21 | 3.00 | 3.79 | 5.66 | 6.00 |
| Long Term Debt / Equity (X) | 0.18 | 0.20 | 0.56 | 0.66 | 0.39 |
| Total Debt / Equity (X) | 0.26 | 0.26 | 0.64 | 0.70 | 0.40 |
| Asset Turnover Ratio (%) | 0.44 | 0.42 | 0.44 | 0.57 | 0.64 |
| Current Ratio (X) | 1.40 | 1.21 | 1.03 | 1.07 | 1.01 |
| Quick Ratio (X) | 0.71 | 0.74 | 0.74 | 0.76 | 0.54 |
| Inventory Turnover Ratio (X) | 4.98 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.98 | 5.47 | 6.36 | 10.87 | 9.58 |
| Interest Coverage Ratio (Post Tax) (X) | 3.06 | 2.54 | 3.15 | 6.24 | 5.30 |
| Enterprise Value (Cr.) | 539.37 | 869.42 | 493.09 | 320.85 | 216.70 |
| EV / Net Operating Revenue (X) | 3.04 | 5.67 | 3.70 | 2.50 | 2.29 |
| EV / EBITDA (X) | 10.58 | 20.93 | 13.04 | 10.19 | 9.12 |
| MarketCap / Net Operating Revenue (X) | 2.62 | 5.22 | 2.86 | 1.80 | 1.86 |
| Price / BV (X) | 1.63 | 3.05 | 2.20 | 1.81 | 1.79 |
| Price / Net Operating Revenue (X) | 2.62 | 5.22 | 2.86 | 1.80 | 1.86 |
| EarningsYield | 0.03 | 0.01 | 0.03 | 0.06 | 0.06 |
After reviewing the key financial ratios for Sakar Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 7.97. This value is within the healthy range. It has increased from 5.63 (Mar 24) to 7.97, marking an increase of 2.34.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.95. This value is within the healthy range. It has increased from 5.63 (Mar 24) to 7.95, marking an increase of 2.32.
- For Cash EPS (Rs.), as of Mar 25, the value is 17.49. This value is within the healthy range. It has increased from 13.66 (Mar 24) to 17.49, marking an increase of 3.83.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 130.06. It has increased from 120.61 (Mar 24) to 130.06, marking an increase of 9.45.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 130.06. It has increased from 120.61 (Mar 24) to 130.06, marking an increase of 9.45.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 80.90. It has increased from 70.51 (Mar 24) to 80.90, marking an increase of 10.39.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 23.23. This value is within the healthy range. It has increased from 19.10 (Mar 24) to 23.23, marking an increase of 4.13.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.72. This value is within the healthy range. It has increased from 10.80 (Mar 24) to 13.72, marking an increase of 2.92.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.81. This value is within the healthy range. It has increased from 7.31 (Mar 24) to 9.81, marking an increase of 2.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.97. This value is within the healthy range. It has increased from 5.37 (Mar 24) to 7.97, marking an increase of 2.60.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.97. This value is within the healthy range. It has increased from 5.37 (Mar 24) to 7.97, marking an increase of 2.60.
- For PBDIT Margin (%), as of Mar 25, the value is 28.71. This value is within the healthy range. It has increased from 27.08 (Mar 24) to 28.71, marking an increase of 1.63.
- For PBIT Margin (%), as of Mar 25, the value is 16.95. This value is within the healthy range. It has increased from 15.31 (Mar 24) to 16.95, marking an increase of 1.64.
- For PBT Margin (%), as of Mar 25, the value is 12.12. This value is within the healthy range. It has increased from 10.36 (Mar 24) to 12.12, marking an increase of 1.76.
- For Net Profit Margin (%), as of Mar 25, the value is 9.85. This value is within the healthy range. It has increased from 7.61 (Mar 24) to 9.85, marking an increase of 2.24.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.85. This value is within the healthy range. It has increased from 7.61 (Mar 24) to 9.85, marking an increase of 2.24.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.13. This value is below the healthy minimum of 15. It has increased from 4.44 (Mar 24) to 6.13, marking an increase of 1.69.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.55. This value is below the healthy minimum of 10. It has increased from 7.12 (Mar 24) to 8.55, marking an increase of 1.43.
- For Return On Assets (%), as of Mar 25, the value is 4.21. This value is below the healthy minimum of 5. It has increased from 3.00 (Mar 24) to 4.21, marking an increase of 1.21.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 0.2. It has decreased from 0.20 (Mar 24) to 0.18, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.26. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.26.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. It has increased from 0.42 (Mar 24) to 0.44, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 24) to 1.40, marking an increase of 0.19.
- For Quick Ratio (X), as of Mar 25, the value is 0.71. This value is below the healthy minimum of 1. It has decreased from 0.74 (Mar 24) to 0.71, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.98. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 4.98, marking an increase of 4.98.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.98. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 5.98, marking an increase of 0.51.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.06. This value is within the healthy range. It has increased from 2.54 (Mar 24) to 3.06, marking an increase of 0.52.
- For Enterprise Value (Cr.), as of Mar 25, the value is 539.37. It has decreased from 869.42 (Mar 24) to 539.37, marking a decrease of 330.05.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.04. This value exceeds the healthy maximum of 3. It has decreased from 5.67 (Mar 24) to 3.04, marking a decrease of 2.63.
- For EV / EBITDA (X), as of Mar 25, the value is 10.58. This value is within the healthy range. It has decreased from 20.93 (Mar 24) to 10.58, marking a decrease of 10.35.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.62. This value is within the healthy range. It has decreased from 5.22 (Mar 24) to 2.62, marking a decrease of 2.60.
- For Price / BV (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 3.05 (Mar 24) to 1.63, marking a decrease of 1.42.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.62. This value is within the healthy range. It has decreased from 5.22 (Mar 24) to 2.62, marking a decrease of 2.60.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sakar Healthcare Ltd:
- Net Profit Margin: 9.85%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.55% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.13% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.06
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.71
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 45 (Industry average Stock P/E: 103.06)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.26
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.85%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Block No. 10/13, Village: Changodar, Ahmedabad District Gujarat 382213 | cs@sakarhealthcare.com http://www.sakarhealthcare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sanjay S Shah | Chairman & Managing Director |
| Mr. Aarsh S Shah | Joint Managing Director |
| Mr. Sunil Marathe | Whole Time Director - Technical |
| Ms. Vishalakshi Chandramouli | Non Executive Director |
| Ms. Rita S Shah | Non Executive Director |
| Mr. Hemendra C Shah | Independent Director |
| Mr. Shailesh B Patel | Independent Director |
| Mr. Prashant C Srivastav | Independent Director |
| Mr. Jignesh Parikh | Independent Director |
| Mrs. Khyati Shah | Independent Director |
| Ms. Megha Samdani | Independent Director |
| Ms. Reeya Kothari | Independent Director |
| Ms. Hiral Patel | Independent Director |
FAQ
What is the intrinsic value of Sakar Healthcare Ltd?
Sakar Healthcare Ltd's intrinsic value (as of 16 November 2025) is 323.61 which is 18.07% lower the current market price of 395.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 879 Cr. market cap, FY2025-2026 high/low of 412/210, reserves of ₹281 Cr, and liabilities of 449 Cr.
What is the Market Cap of Sakar Healthcare Ltd?
The Market Cap of Sakar Healthcare Ltd is 879 Cr..
What is the current Stock Price of Sakar Healthcare Ltd as on 16 November 2025?
The current stock price of Sakar Healthcare Ltd as on 16 November 2025 is 395.
What is the High / Low of Sakar Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sakar Healthcare Ltd stocks is 412/210.
What is the Stock P/E of Sakar Healthcare Ltd?
The Stock P/E of Sakar Healthcare Ltd is 45.0.
What is the Book Value of Sakar Healthcare Ltd?
The Book Value of Sakar Healthcare Ltd is 136.
What is the Dividend Yield of Sakar Healthcare Ltd?
The Dividend Yield of Sakar Healthcare Ltd is 0.00 %.
What is the ROCE of Sakar Healthcare Ltd?
The ROCE of Sakar Healthcare Ltd is 8.54 %.
What is the ROE of Sakar Healthcare Ltd?
The ROE of Sakar Healthcare Ltd is 6.48 %.
What is the Face Value of Sakar Healthcare Ltd?
The Face Value of Sakar Healthcare Ltd is 10.0.